Amicus Therapeutics Inc
FOLD
Market Cap$3.01B
Close$
$12.62
23.2% upside
Current Fair Value
23.2% upsideUndervalued by 23.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.01 Billion |
|---|---|
| Enterprise Value | $3.11 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.51 |
| Beta | 0.0 |
| Outstanding Shares | 296,176,419 |
| Avg 30 Day Volume | 2,785,978 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -19.87 |
|---|---|
| PEG | 50.41 |
| Price to Sales | 10.25 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.8 |
| Enterprise Value to EBIT | -42.37 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 2.42 |
Revenue Sources
No data
ESG Score
No data
About Amicus Therapeutics Inc
CEO: John Crowley